The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | EHA: AML immuno-oncology updates
Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, discusses progress in immuno-oncology for the treatment of acute myeloid leukemia (AML). Specifically discussed is the identification of a new checkpoint, CD47, which is expressed on macrophages within the tumor microenvironment as well as compound CAR-T cells and BiTEs presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
